- Home
- FIGS vs SDGR Comparison
FIGS vs SDGR Comparison
Compare FIGS & SDGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FIGS
- SDGR
- Stock Information
- Founded
- FIGS 2013
- SDGR 1990
- Country
- FIGS United States
- SDGR United States
- Employees
- FIGS N/A
- SDGR N/A
- Industry
- FIGS Apparel
- SDGR Biotechnology: Pharmaceutical Preparations
- Sector
- FIGS Consumer Discretionary
- SDGR Health Care
- Exchange
- FIGS Nasdaq
- SDGR Nasdaq
- Market Cap
- FIGS 1.2B
- SDGR 1.3B
- IPO Year
- FIGS 2021
- SDGR 2020
- Fundamental
- Price
- FIGS $9.62
- SDGR $16.56
- Analyst Decision
- FIGS Hold
- SDGR Buy
- Analyst Count
- FIGS 5
- SDGR 7
- Target Price
- FIGS $8.60
- SDGR $26.57
- AVG Volume (30 Days)
- FIGS 2.7M
- SDGR 1.1M
- Earning Date
- FIGS 11-06-2025
- SDGR 11-05-2025
- Dividend Yield
- FIGS N/A
- SDGR N/A
- EPS Growth
- FIGS 91.65
- SDGR N/A
- EPS
- FIGS 0.11
- SDGR N/A
- Revenue
- FIGS $581,034,000.00
- SDGR $256,951,000.00
- Revenue This Year
- FIGS $4.73
- SDGR $22.73
- Revenue Next Year
- FIGS $3.67
- SDGR $19.85
- P/E Ratio
- FIGS $91.90
- SDGR N/A
- Revenue Growth
- FIGS 5.90
- SDGR 32.90
- 52 Week Low
- FIGS $3.57
- SDGR $15.99
- 52 Week High
- FIGS $10.24
- SDGR $28.47
- Technical
- Relative Strength Index (RSI)
- FIGS 65.50
- SDGR 33.39
- Support Level
- FIGS $8.95
- SDGR $16.80
- Resistance Level
- FIGS $10.24
- SDGR $17.57
- Average True Range (ATR)
- FIGS 0.52
- SDGR 0.89
- MACD
- FIGS 0.04
- SDGR -0.26
- Stochastic Oscillator
- FIGS 77.66
- SDGR 10.48
About FIGS FIGS Inc.
FIGS Inc is a healthcare apparel company. The Company designs and sells scrubwear and non-scrubwear, such as outerwear, underscrubs, footwear, compression socks, lab coats, loungewear and other apparel. The Company generates maximum revenue from United States. Sales are generated through the Company's digital platforms.
About SDGR Schrodinger Inc.
Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.